Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 422

1.

Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia.

Král Z, Michalka J, Móciková H, Marková J, Sýkorová A, Belada D, Jungová A, Vokurka S, Lukášová M, Procházka V, Ďuraš J, Hájek R, Dušek L, Drgoňa Ľ, Ladická M, Ballová V, Vranovský A.

J Cancer. 2019 Aug 28;10(21):5041-5048. doi: 10.7150/jca.29308. eCollection 2019.

2.

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination.

Garcés JJ, Simicek M, Vicari M, Brozova L, Burgos L, Bezdekova R, Alignani D, Calasanz MJ, Growkova K, Goicoechea I, Agirre X, Pour L, Prosper F, Rios R, Martinez-Lopez J, Millacoy P, Palomera L, Del Orbe R, Perez-Montaña A, Garate S, Blanco L, Lasa M, Maiso P, Flores-Montero J, Sanoja-Flores L, Chyra Z, Vdovin A, Sevcikova T, Jelinek T, Botta C, El Omri H, Keats J, Orfao A, Hajek R, San-Miguel JF, Paiva B.

Leukemia. 2019 Oct 8. doi: 10.1038/s41375-019-0588-4. [Epub ahead of print]

PMID:
31595039
3.

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.

Bringhen S, D'Agostino M, Paris L, Ballanti S, Pescosta N, Spada S, Pezzatti S, Grasso M, Rota-Scalabrini D, De Rosa L, Pavone V, Gazzera G, Aquino S, Poggiu M, Santoro A, Gentile M, Baldini L, Petrucci MT, Tosi P, Marasca R, Cellini C, Palumbo A, Falco P, Hájek R, Boccadoro M, Larocca A.

Haematologica. 2019 Oct 3. pii: haematol.2019.226407. doi: 10.3324/haematol.2019.226407. [Epub ahead of print]

4.

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.

Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, Gunsilius E, Krenosz KJ, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N.

Br J Cancer. 2019 Sep 27. doi: 10.1038/s41416-019-0581-8. [Epub ahead of print]

PMID:
31558804
5.

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.

Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, Hajek R, Gunsilius E, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Rumpold H, Pour L, Jelinek T, Krenosz KJ, Meckl A, Nolte S, Melchardt T, Greil R, Zojer N.

Leuk Lymphoma. 2019 Sep 26:1-10. doi: 10.1080/10428194.2019.1666381. [Epub ahead of print]

PMID:
31556753
6.

CAR-T cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.

Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, San Miguel JF, Einsele H.

Haematologica. 2019 Aug 22. pii: haematol.2019.224204. doi: 10.3324/haematol.2019.224204. [Epub ahead of print]

7.

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.

Hájek R, Delforge M, Raab MS, Schoen P, DeCosta L, Spicka I, Radocha J, Pour L, Gonzalez-McQuire S, Bouwmeester W.

Br J Haematol. 2019 Aug 6. doi: 10.1111/bjh.16105. [Epub ahead of print]

PMID:
31388996
8.

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.

Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangialosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hajek R, Boccadoro M, Bringhen S.

Haematologica. 2019 Jun 27. pii: haematol.2019.220657. doi: 10.3324/haematol.2019.220657. [Epub ahead of print]

9.

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, D'Rozario JM, Dimopoulos MA, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, Hájek R, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV.

Ann Hematol. 2019 Sep;98(9):2139-2150. doi: 10.1007/s00277-019-03739-2. Epub 2019 Jun 25.

10.

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.

Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, Nagler A, Hajek R, Offidani M, Liberati AM, Sonneveld P, Cavo M, Corradini P, Boccadoro M.

Haematologica. 2019 Jun 20. pii: haematol.2019.219139. doi: 10.3324/haematol.2019.219139. [Epub ahead of print]

11.

Extramedullary disease in multiple myeloma - controversies and future directions.

Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R.

Blood Rev. 2019 Jul;36:32-39. doi: 10.1016/j.blre.2019.04.002. Epub 2019 Apr 13. Review.

12.

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J.

Blood. 2019 May 2;133(18):1953-1963. doi: 10.1182/blood-2018-09-874396. Epub 2019 Feb 28.

PMID:
30819926
13.

Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?

Steiner N, Hajek R, Nachbaur D, Borjan B, Sevcikova S, Göbel G, Gunsilius E.

Dis Markers. 2019 Jan 27;2019:1806034. doi: 10.1155/2019/1806034. eCollection 2019.

14.

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.

Ludwig H, Moreau P, Dimopoulos MA, Mateos MV, Kaiser M, Hajek R, Feng S, Cocks K, Buchanan J, Weisel K.

Blood Cancer J. 2019 Feb 22;9(3):23. doi: 10.1038/s41408-019-0181-0.

15.

Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.

Maisnar V, Stefanikova Z, Spicka I, Pour L, Minarik J, Flochova E, Radocha J, Gregora E, Stecova N, Jelinek T, Jungova A, Kralikova E, Brozova L, Hajek R.

Neoplasma. 2019 May 23;66(3):499-505. doi: 10.4149/neo_2018_180824N644. Epub 2019 Feb 14.

PMID:
30784289
16.

Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma.

Thomsen H, Chattopadhyay S, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Späth F, Houlston R, Goldschmidt H, Hemminki K, Försti A.

Leukemia. 2019 Jul;33(7):1817-1821. doi: 10.1038/s41375-019-0396-x. Epub 2019 Feb 8. No abstract available.

PMID:
30737484
17.

Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making.

Gonzalez-McQuire S, Dimopoulos MA, Weisel K, Bouwmeester W, Hájek R, Campioni M, Bennison C, Xu W, Pantiri K, Hensen M, Terpos E, Knop S.

MDM Policy Pract. 2019 Jan 17;4(1):2381468318814253. doi: 10.1177/2381468318814253. eCollection 2019 Jan-Jun.

18.

Long Non-Coding RNAs in Multiple Myeloma.

Butova R, Vychytilova-Faltejskova P, Souckova A, Sevcikova S, Hajek R.

Noncoding RNA. 2019 Jan 24;5(1). pii: E13. doi: 10.3390/ncrna5010013. Review.

19.

CD38 targeted treatment for multiple myeloma.

Jelínek T, Mihályová J, Hájek R.

Vnitr Lek. Fall 2018;64(10):939-948.

PMID:
30590941
20.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.

PMID:
30545780
21.

Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis.

Radocha J, Hájek R, Brožová L, Pour L, Špička I, Minařík J, Gregora E, Jungová A, Jelínek T, Heindorfer A, Sýkora M, Maisnar V.

Ann Hematol. 2019 Apr;98(4):951-962. doi: 10.1007/s00277-018-3568-2. Epub 2018 Dec 11.

PMID:
30539278
22.

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.

Jelinek T, Paiva B, Hajek R.

Front Immunol. 2018 Nov 16;9:2431. doi: 10.3389/fimmu.2018.02431. eCollection 2018. Review.

23.

Decreasing disruptive behaviour during routine dental visits: a video modelling intervention for young children.

Hine JF, Hajek RT, Roberts HJ, Allen KD.

Int Dent J. 2019 Aug;69(4):265-272. doi: 10.1111/idj.12457. Epub 2018 Nov 29.

PMID:
30488954
24.

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.

Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P.

Blood Cancer J. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7.

25.

Strategies preventing deep sternal wound infection in cardiac surgery review.

Šimek M, Hájek R, Kaláb M, Klváček A, Zálešák B.

Rozhl Chir. Summer 2018;97(9):414-418. Review.

PMID:
30470121
26.

Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma.

Jelinek T, Adamusova L, Popkova T, Tvrda I, Smejkalova J, Simicek M, Salounova D, Kascak M, Mihalyova J, Plonkova H, Duras J, Navratil M, Hajek R, Koristek Z.

Bone Marrow Transplant. 2019 Jul;54(7):1107-1114. doi: 10.1038/s41409-018-0396-x. Epub 2018 Nov 20.

PMID:
30459429
27.

Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients.

Almasi M, Besse L, Brozova L, Jarkovsky J, Bezdekova R, Pour L, Minarik J, Kessler P, Pavlíček P, Roziakova L, Penka M, Hájek R, Vasku A, Sevcikova S.

Klin Onkol. Spring 2018;31(3):213-229. doi: 10.14735/amko2018213.

PMID:
30441975
28.

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC.

Blood Cancer J. 2018 Nov 9;8(11):109. doi: 10.1038/s41408-018-0141-0. Review.

29.

Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population.

Minarik J, Pour L, Maisnar V, Spicka I, Jungova A, Jelinek T, Brozova L, Krhovska P, Scudla V, Hajek R.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Sep;163(3):279-283. doi: 10.5507/bp.2018.064. Epub 2018 Nov 6.

30.

Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).

Jelinek T, Mihalyova J, Kascak M, Duras J, Popkova T, Benkova K, Richterova P, Plonkova H, Zuchnicka J, Broskevicova L, Huvarova L, Cerna L, Growkova K, Simicek M, Havel M, Gumulec J, Navratil M, Koristek Z, Paiva B, Hajek R.

Am J Hematol. 2019 Jan;94(1):E35-E37. doi: 10.1002/ajh.25331. Epub 2018 Nov 25. No abstract available.

PMID:
30370955
31.

[Penetrating Injuries of the Heart and Great Vessels - Fifteen Years of Experience of the Cardiac Surgery Service as a Part of the Major Trauma Centre].

Šimek M, Konečný J, Hájek R, Čižmář I, Kutěj V, Lonský V.

Acta Chir Orthop Traumatol Cech. 2018;85(2):144-148. Czech.

PMID:
30295602
32.

From open packing to negative wound pressure therapy: A critical overview of deep sternal wound infection treatment strategies after cardiac surgery.

Simek M, Chudoba A, Hajek R, Tobbia P, Molitor M, Nemec P.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Sep 14. doi: 10.5507/bp.2018.053. [Epub ahead of print]

PMID:
30215435
33.

The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma.

Steiner N, Hajek R, Sevcikova S, Borjan B, Untergasser G, Göbel G, Gunsilius E.

Anticancer Res. 2018 Sep;38(9):5087-5092. doi: 10.21873/anticanres.12828.

PMID:
30194153
34.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M.

JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

35.

The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets.

Steiner N, Müller U, Hajek R, Sevcikova S, Borjan B, Jöhrer K, Göbel G, Pircher A, Gunsilius E.

PLoS One. 2018 Aug 10;13(8):e0202045. doi: 10.1371/journal.pone.0202045. eCollection 2018.

36.

A Pilot Study Evaluating Organochlorine and Organophosphate Pesticide Exposure in Children and Adolescents of Mexican Descent Residing in Hidalgo County, Texas.

Hernandez M, Hernández-Valero MA, García-Prieto C, Patterson DG, Hajek RA, Recinos I, Lopez DS, Li Y, Jones LA, Hawk E.

J Immigr Minor Health. 2019 Aug;21(4):751-760. doi: 10.1007/s10903-018-0791-9.

PMID:
30066057
37.

HILIC/ESI-MS determination of gangliosides and other polar lipid classes in renal cell carcinoma and surrounding normal tissues.

Hájek R, Lísa M, Khalikova M, Jirásko R, Cífková E, Študent V Jr, Vrána D, Opálka L, Vávrová K, Matzenauer M, Melichar B, Holčapek M.

Anal Bioanal Chem. 2018 Oct;410(25):6585-6594. doi: 10.1007/s00216-018-1263-8. Epub 2018 Jul 28.

PMID:
30054694
38.

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E.

Leukemia. 2018 Sep;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7. Epub 2018 Jul 23. Review.

39.

Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.

Jurczyszyn A, Davila J, Kortüm KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wiśniewska-Piąty K, Waszczuk-Gajda A, Crusoe E, Hajek R, Robak P, Raźny M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH.

Leuk Lymphoma. 2019 Feb;60(2):471-476. doi: 10.1080/10428194.2018.1480766. Epub 2018 Jul 22.

PMID:
30033832
40.

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.

Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, Hajek R, Groarke J, Lyon AR, Batty GN, Ro S, Huang M, Iskander KS, Lenihan D.

Blood Adv. 2018 Jul 10;2(13):1633-1644. doi: 10.1182/bloodadvances.2017015545. Review.

41.

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.

Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząśko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH.

Leuk Lymphoma. 2019 Jan;60(1):118-123. doi: 10.1080/10428194.2018.1473574. Epub 2018 Jul 2.

PMID:
29965787
42.

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.

Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia.

Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5. Review.

PMID:
29958569
43.

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.

San-Miguel JF, Echeveste Gutierrez MA, Špicka I, Mateos MV, Song K, Craig MD, Bladé J, Hájek R, Chen C, Di Bacco A, Estevam J, Gupta N, Byrne C, Lu V, van de Velde H, Lonial S.

Haematologica. 2018 Sep;103(9):1518-1526. doi: 10.3324/haematol.2017.185991. Epub 2018 Jun 28.

44.

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.

Radocha J, Maisnar V, Pour L, Špička I, Minařík J, Szeligová L, Pavlíček P, Jungová A, Krejčí M, Pika T, Straub J, Brožová L, Stejskal L, Heindorfer A, Jindra P, Kessler P, Mikula P, Sýkora M, Wróbel M, Jarkovský J, Hájek R.

Cancer Med. 2018 Aug;7(8):4132-4145. doi: 10.1002/cam4.1620. Epub 2018 Jun 21.

45.

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.

Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 28.

PMID:
29910180
46.

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.

Hájek R, Jarkovsky J, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Campioni M, DeCosta L, Treur M, Gonzalez-McQuire S, Bouwmeester W.

Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):e219-e240. doi: 10.1016/j.clml.2018.04.003. Epub 2018 Apr 17.

PMID:
29793653
47.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2. Review.

48.

The start of a new wave: Developments in proteasome inhibition in multiple myeloma.

Yong K, Gonzalez-McQuire S, Szabo Z, Schoen P, Hajek R.

Eur J Haematol. 2018 Mar 30. doi: 10.1111/ejh.13071. [Epub ahead of print] Review.

PMID:
29603798
49.

Venetoclax: A new wave in hematooncology.

Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R.

Exp Hematol. 2018 May;61:10-25. doi: 10.1016/j.exphem.2018.02.002. Epub 2018 Mar 2. Review.

PMID:
29477371
50.

Newly designed 11-gene panel reveals first case of hereditary amyloidosis captured by massive parallel sequencing.

Chyra Kufova Z, Sevcikova T, Januska J, Vojta P, Boday A, Vanickova P, Filipova J, Growkova K, Jelinek T, Hajduch M, Hajek R.

J Clin Pathol. 2018 Aug;71(8):687-694. doi: 10.1136/jclinpath-2017-204978. Epub 2018 Feb 17.

Supplemental Content

Support Center